Compare S&P Global Inc (SPGI) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P Global Inc vs 10X Genomics Inc — how do they compare? S&P Global Inc trades at $404.76 (market cap $120.48B), while 10X Genomics Inc trades at $58.75 (market cap $7.61B). The key difference: S&P Global Inc is far larger — about 15.8× 10X Genomics Inc's market cap, and S&P Global Inc pays a 0.95% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| SPGI | TXG | |
|---|---|---|
Market Cap | $120.48B | $7.61B |
Sector | Financials | Health |
52-Week High | $534.79 | $58.57 |
52-Week Low | $370.42 | $11.34 |
Enterprise Value | $131.97B | $7.14B |
Dividend Yield | 0.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
S&P Global (SPGI) trades at $410.94, up 0.67% on the day, with a bearish technical signal despite strong fundamentals. Revenue grew to $15.34B in 2025, with a net income margin of 30.54%, while analyst consensus remains overwhelmingly bullish with a $523.20 price target. Recent news highlights AI integration with Microsoft and strong Q2 2026 earnings beats.
The outlook is positive given robust profitability and strategic expansions, but risks include technical weakness and debt levels. Upside potential exists if the stock rebounds toward analyst targets, though investors should monitor execution against high expectations.
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
